California made a big bet on producing its own insulin. There’s no ‘date certain’ for delivery
California made a bold announcement that it would manufacture a state-branded, low-cost insulin. It still is not here.
Investor's Business Daily on MSN16m
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback